Abstract: Discussed is a battery that may include at least one battery module including at least one battery cell, a case tray configured to support the at least one battery module, a case cover coupled with the case tray to cover the at least one battery module, a sealing gasket disposed between the case tray and the case cover to prevent penetration of moisture or foreign substance into the at least one battery module, and a reinforcing unit provided to the case cover to be disposed adjacent to the sealing gasket and configured to prevent twisting of the case cover when the case tray and the case cover are coupled.

Abstract: A railess variable seatback type rear seat includes: a linear movement device configured to convert a rotation of a motor into a linear movement; a sliding movement device configured to convert the linear movement into a sliding movement in which a seat cushion is pushed forward or backward; and a reclining angle change device configured to convert the sliding movement into a reclining movement, and to fold a seatback, which is connected to the seat cushion, forward or to recline the seatback backward.

Abstract: The present invention relates to an auxiliary precursor, a thin film precursor composition, a method of forming a thin film using the thin film precursor composition, and a semiconductor substrate fabricated using the method. The present invention provides the thin film precursor composition including a thin film precursor compound and a compound having a predetermined structure that exhibits reaction stability as the auxiliary precursor. By using the thin film precursor composition in a thin film deposition process, side reactions may be suppressed, and thin film growth rate may be appropriately controlled. In addition, since process by-products are removed from a thin film, even when a thin film is formed on a substrate having a complicated structure, step coverage and the thickness uniformity and resistivity characteristics of the thin film may be greatly improved.

Abstract: Discussed is a battery pack that may include at least one battery module including at least one battery cell; a case tray configured to support the at least one battery module; a tray cover coupled to the case tray; and at least one bushing gasket configured to connect the case tray and the tray cover and to support the case tray on a plurality of points.

Abstract: A wafer level package includes: a substrate; an element portion disposed on one surface of the substrate; a cap disposed on the substrate to cover the element portion; a connection portion electrically connected to the element portion; and a bonding portion disposed on an outer side of the connection portion, wherein the bonding portion is disposed on a first surface of one of the substrate and the cap, wherein one end portion of the connection portion is disposed on a second surface having a step difference from the first surface, and wherein the connection portion and the bonding portion are formed of a eutectic material.

Abstract: The present invention relates to a composition for preventing or treating heart failure including TREM2 protein or a fragment thereof as an active ingredient. The TREM2 protein or fragment thereof according to the present invention can be prepared as a soluble form and used as an injection, and when injected into the body, it promotes functional and structural improvement of the infarcted heart, and is effective for preventing or treating heart failure, and more specifically, it can be advantageously used for preventing or treating heart failure that appears as a sequela of myocardial infarction.

Abstract: The present disclosure relates to an organic electroluminescent compound, a plurality of host materials, and an organic electroluminescent device comprising the same. By comprising the compound according to the present disclosure or by comprising a specific combination of compounds according to the present disclosure as a plurality of host materials, it is possible to produce an organic electroluminescent device having improved driving voltage, luminous efficiency, and/or lifetime properties compared to the conventional organic electroluminescent devices.

Abstract: A chip-on-film package includes: a lower base film including a first surface and a second surface, which are opposite to each other; an upper base film including a third surface and a fourth surface, which are opposite to each other, and is disposed on the lower base film; a first semiconductor chip mounted on the second surface of the lower base film; a second semiconductor chip mounted on the third surface of the upper base film; and an interposer film interposed between the lower and upper base films, wherein the second and third surfaces face each other.

Abstract: A semiconductor package includes a film substrate; a wiring layer provided on the film substrate; and a semiconductor chip provided on the wiring layer and electrically connected to the wiring layer. The film substrate includes a first layer, wherein the first layer is an insulating layer having the wiring layer thereon. The film substrate further includes a second layer, wherein the second layer is attached to a bottom of the first layer and comprises a gas. The second layer is configured to be peeled off of the first layer.

Abstract: The present invention relates to a composition for preventing, ameliorating, or treating neurological diseases related to copper metabolism, wherein the composition comprises a multi-copper oxidase peptide. A multi-copper oxidase-derived peptide according to the present invention was found to be highly effective for treating myelination damage in the nervous system in a copper-induced neurological disease model, thus indicating that the multi-copper oxidase-derived peptide according to the present invention has a significant therapeutic effect on neurological diseases. Therefore, the multi-copper oxidase-derived peptide can be used in various ways in the field of preventing, ameliorating, and treating neurological diseases.

Abstract: A charging connection device for a drone according to an embodiment of the present invention comprises: a core (20) installed on a drone (10); an electrically conductive member (30) positioned on the outer contour of the core (20) and formed o a conductive material; and a tension unit (40) positioned between the core (20) and the electrically conductive member (30) and absorbing shock transmitted from the electrically conductive member (30).

Abstract: The present invention relates to a composition for the prevention, amelioration, or treatment of urination-related disases, comprising cephalotocin. The cephalotocin according to the present invention modulates oxytocin receptors and vasopressin receptors, and has the effect of reducing urine volume by promoting water reabsorption in the kidneys. This means that cephalotocin has a significant antidiuretic effect, and thus, the cephalotocin of the present invention can be variously used in the field of prevention, amelioration, or treatment of urinary disorders or urination-related diseases.

Abstract: The present invention relates to a crystalline form of a salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and a pharmaceutical composition containing the same. The crystalline form of the salt of the compound can be easily used for preparing a pharmaceutical composition containing the same as an active ingredient.

Abstract: The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.

Abstract: Disclosed are novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts thereof, optical isomers, hydrates, and solvates thereof as well as uses thereof. More specifically, the novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts, optical isomers, hydrates, solvates show inhibition activity of EZH1 (Enhancer of zeste homolog 1) and/or EZH2 (Enhancer of zeste homolog 2) activity. Pharmaceutical compositions containing the compound is also disclosed.

Abstract: The present invention relates to: a biomarker composition for diagnosing or predicting the prognosis of thyroid cancer, comprising a preparation capable of detecting a mutation in a PLEKHS1 promoter gene; and a use thereof. The biomarker composition for diagnosing or predicting the prognosis of thyroid cancer of the present invention confirms whether a mutation is present in a PLEKHS1 promoter gene, and thus can provide information needed for diagnosing metastatic (distant metastatic) differentiated thyroid cancer, and also confirms whether a mutation is present in BRAF, TERT promoter, three types of RAS and a TP53 gene in addition to the PLEKHS1 promoter gene, and thus, with respect to radioactive iodine therapy response and survival, can classify the prognosis of a metastatic differentiated thyroid cancer patient into one of three prognosis groups, and predict the same.

Abstract: The present invention relates to a compound, 4-amino-N-(1-((3-chloro-2-fluoro-4-hydroxyphenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide, and pharmaceutically acceptable salts thereof having inhibitory activity for protein kinases.

Abstract: The present invention relates to an Octopus minor-specific octopressin peptide comprising the amino acid sequence of SEQ ID NO: 3, and the peptide, by promoting the brooding behaviors of mother Octopus minor to protect her eggs, may increase the hatched larva rate when applied to partial cultivation of octopuses, and thus may be used for the growth of octopus resources.

Abstract: Disclosed are novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts thereof, optical isomers, hydrates, and solvates thereof as well as uses thereof. More specifically, the novel dioxoisoquinolinone derivative compounds, pharmaceutically acceptable salts, optical isomers, hydrates, solvates show inhibition activity of EZH1 (Enhancer of zeste homolog 1) and/or EZH2 (Enhancer of zeste homolog 2) activity. Pharmaceutical compositions containing the compound is also disclosed.